Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Kymera suffers Sanofi setback but secures $750M Gilead deal
Sanofi is pulling back from its lead IRAK4 degrader, switching to a preclinical prospect, while Gilead has inked an oncology deal with Kymera.
Nick Paul Taylor
Jun 25, 2025 9:31am
Gilead lays off 36 people after axing Oceanside expansion plan
Jun 16, 2025 9:53am
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Jun 13, 2025 8:00am
FDA slaps clinical hold on multiple Gilead HIV trials
Jun 10, 2025 10:48am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study
May 31, 2025 7:00pm
